Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Ficlatuzumab (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 18 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Aug 2019 Planned End Date changed from 1 Jun 2020 to 26 Jun 2020.
- 18 Aug 2019 Planned primary completion date changed from 1 Dec 2019 to 27 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History